ASCO 2020：11项中国研究入选口头简报，17项Poster简报

所致亚洲地区上新冠鼠疫冲击，顺延于5月29日~6月2日在芝加哥举行的美国临床学但会（ASCO）年但会去年将首次以该线上基本举办地，这是目前最大规模的该线上盛但会。直到现在，全体但会议的简介题目公告，共103个sessions，里国共有11项数据比对被选为口头报告，17项被选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或希亚替尼加卡培他滨运用于HER2+结核乳腺乳癌（PHOEBE）：一项III期随机次测试。

交响乐：结核乳腺乳癌

原作者：里国医学科学院养老院徐兵河数据比对员、马飞数据比对员，武汉大学附属养老院胡夕春数据比对员等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴适度乳腺乳癌国际标准治疗法后卡培他滨确保节拍放射治疗的III期次测试（SYSUCC-001）。

交响乐：乳腺乳癌—大面积/区外/辅助治疗法

原作者：武汉大学防治外围王以树森数据比对员等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用结核脑的表型特性来预见脑脊液里循环DNA检测的概率: 上新工具对抗从前输掉

交响乐：上新工具妥善解决从前难题

原作者：李美芹 李德兰等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

利诺非尼对里拉拉非尼作为中晚期胃细胞膜乳癌的主力治疗法：一项闭馆ID、随机、多外围II/III期次测试。

交响乐：上皮细胞膜乳癌—肠胃气管、胰腺和实无

原作者：四川大学华西养老院毕锋数据比对员、里国人民武装警察部队二七养老院秦叔逵数据比对员等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国中晚期胃乳癌病症阿帕替尼主力治疗法：一项随机、抗抑郁药对应、双盲III期数据比对

交响乐：上皮细胞膜乳癌—肠胃气管、胰腺和实无

原作者：里国人民武装警察部队二七养老院秦叔逵数据比对员、四川大学华西养老院李秋数据比对员等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中晚期患适度卵巢乳癌二次细胞膜减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

研讨：外科乳乳癌

原作者：武汉大学附属里山养老院臧荣余数据比对员等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治适度子宫切除术后辅助治疗法里的序贯放放射治疗对比单独恶性肿瘤或联动放放射治疗（STARS数据比对）：一项随机、对应、闭馆ID的III期次测试。

全体但会议：外科乳乳癌

原作者：武汉大学防治外围黄鹤数据比对员、刘继红数据比对员等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比放射治疗运用于可切除的EGFR等位基因的N1-N2期NSCLC-随机III期临床次测试的最终大体上猎食比对。

研讨：心肌梗塞—非小细胞膜大面积-区外/小细胞膜/其他腹部

原作者：东莞市人民养老院吴一龙数据比对员等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR等位基因辄集里于非小细胞膜心肌梗塞病症主力代谢物激酶胺联合行动或不联合行动努力机动部队大面积恶性肿瘤：III期闭馆ID临床随机次测试（SINDAS）的里期结果（NCT02893332）。

研讨：心肌梗塞-非小细胞膜集里于

原作者：重庆市人民养老院曾铭数据比对员等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序适度死亡-1（PD-1）的人源化IgG4单克隆抗体联合行动阿昔替尼运用于结核黏膜皮肤癌病症的Ib期数据比对的总猎食期和脊椎动物标志物比对。

研讨：皮肤癌/皮肤乳癌

原作者：里国人民大学养老院郭军、盛锡楠数据比对员等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全适度和结果：通用CAR-T细胞膜首次人体次测试治疗法患/难治适度T细胞膜急适度淋巴细胞膜肠胃癌（r/r T-ALL）的安全适度和。全体但会议：开发里的治疗法技术-免疫治疗法。原作者：王以欣欣等简介：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利抗病毒在中晚期气管鳞状细胞膜乳癌病症里的运用于：一项随机的闭馆IDII期次测试（ORIENT-2）。全体但会议：上皮细胞膜乳癌-肠胃气管乳癌、胰腺乳癌和实无道乳癌原作者：徐建明数据比对员等简介：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异适度CAR-T细胞膜对髓母细胞膜瘤的消弭适度治疗法全体但会议：里枢神经系统原作者：代红久、孙斌、杨东、徐晖、徐毛毛、魏佳、赵旭东简介：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中晚期错配修复缺失病症里的运用于全体但会议：开发里的治疗法学-免疫治疗法原作者：沈琳数据比对员等简介：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART治疗法患/难治适度ACUTE淋巴细胞膜肠胃癌/淋巴瘤的尚未有人体临床次测试全体但会议: 开发适度治疗法学-免疫治疗法原作者简介：张明志，杨林等简介：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度甲基（T）联合行动应运用于中晚期单一瘤病症的Ib期数据比对全体但会议：发展适度治疗法学；还有分子靶向用药和脊椎动物学原作者：龚继芳，沈琳数据比对员等简介：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动糖类和nedaplatin治疗法患适度或结核气管鳞状细胞膜乳癌（ESCC）病症的II期数据比对。全体但会议：上皮细胞膜乳癌-肠胃气管、胰腺和实无道乳癌的数据比对原作者：王以志过关斩将，李玉红，王以德申，王以凤华，任超，谭琼 王以志过关斩将、李玉红、王以德深、王以凤华、任超、谭琼简介：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体但会议：上皮细胞膜乳癌-肠胃气管乳癌、胰腺乳癌和实无管乳癌的主力治疗法原作者：宋艳等简介：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种唾液外体环状RNA分类器运用于初始前列腺时检测高等级乳癌的唾液外体环状RNA分类器：一项多外围的回顾适度数据比对全体但会议：泌尿系统生殖系统乳乳癌；还有-乳癌、睾丸乳癌和乳癌原作者简介：Liaoyuan Li等简介：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积中晚期宫颈乳癌并发放射治疗后的辅助放射治疗全体但会议: 外科乳乳癌原作者简介： 李珉珉等简介：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法骨髓髓适度乳癌的关联适度：基于ALTER01031次测试的比对。但会话：黑纹原作者：沈阳市养老院从前练数据比对员简介：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、较小和成年对安洛替尼治疗法后病症结局的冲击: ALTER01031的亚组比对全体但会议：黑纹原作者：沈阳市养老院从前练数据比对员简介：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对预见I-IIIA期非小细胞膜心肌梗塞（NSCLC）病症术后患: GASTO1035和GASTO1018的结果全体但会议：心肌梗塞-非小细胞膜大面积-这两项/小细胞膜/小细胞膜/其他胸科乳乳癌原作者：Si-Yu Wang等简介：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞膜心肌梗塞（NSCLC）里EGFR代谢物激酶胺的上新型耐药机制全体但会议:心肌梗塞-非小细胞膜结核心肌梗塞原作者简介：赵昕，金恰巧，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金恰巧、满宇、欧秋香、华宝、薛武、杨绍、范敏简介：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试里中晚期皮肤癌总猎食的替代终点全体但会议：皮肤癌/皮肤乳癌原作者：聂润聪，袁书过关斩将，李元芳，陈英波，周志伟 聂润聪、袁书过关斩将、李元芳、陈英波、周志伟简介：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法患或结核原发适度恶适度骨病症的II期数据比对全体但会议： 溃疡原作者：唐丽娜，牛晓辉，王以震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王以振、蔡启庆、涂崇奇、范正福、杨瑶简介：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评分安罗替尼在中晚期溃疡病症多该线治疗法里的安全适度和。全体但会议：溃疡原作者：姚伟涛，的王以室过关斩将，张春，王以欣，杜上新辉，田志浩，牛晓颖 姚伟涛、的王以室过关斩将、张春、王以鑫、杜鑫辉、田志超、牛晓英简介：11526宣传品：414